


Dr. Scott Armstrong, MD
Dr. Scott Armstrong, MD is a pediatric hematologist oncologist in Boston, MA and has over 25 years of experience in the medical field. He graduated from University of Texas Southwestern Medical Center in 1996. He is affiliated with Boston Children's Hospital. He is accepting new patients.
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
450 Brookline Ave # Dana-Far Boston, MA 02215Biography
- Dr. Scott Armstrong, MD

Save money with free prescription discounts
Experience Check
Search for experience in a specific area
Insurance Check
Search for your insurance carrier and choose your plan type
Dr. Armstrong's Reviews
Overall Patient Satisfaction
About Me
biography
Scott A. Armstrong, MD, PhD, became the President of Dana-Farber/Boston Children's Cancer and Blood Disorders Center in 2019 and has been Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute since 2016. He also serves...read morePediatric Hematology & Oncology
*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.
Dana-farber/boston Children's Cancer And Blood Disorders Center
Fellowship Hospital, 2001Boston Combined Residency Program (bcrp)
Internship Hospital, 1998Boston Combined Residency Program In Pediatrics
Residency Hospital, 1998University Of Texas Southwestern Medical Center
Medical School, 1996
Healthgrades receives board action history for physicians and physician assistants. The information displayed here is sourced from independent information providers, such as state board websites, and may not be the most up-to-date information. Healthgrades makes no representations with respect to the accuracy of any information provided here and assumes no responsibility or liability for such information.
Learn more about medical license public record checkHOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis, 2018-09-27
The Wnt/ß-catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML, 2010-03-26
Chromatin modifications as therapeutic targets in MLL-rearranged Leukemia, 2012-08-03
MLL-rearranged Leukemia is Dependent on Aberrant H3K79 Methylation by DOT1L, 2011-07-12
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL, 2015-02-16
H3K79 methylation profiles define murine and human MLL-AF4 leukemias, 2008-11-04
MEN1mutations mediate clinical resistance to Menin inhibition, 2023-03-15
Self-renewal related signaling in myeloid leukemia stem cells, 2011-07-29
A non-catalytic function of SETD1A regulates Cyclin-K and the DNA damage response, 2018-02-22
Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia, 2023-03-01
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia, 2023-08-30
Chromatin modifying enzymes as modulators of reprogramming, 2012-03-04
Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition, 2020-06-30
Histone acetyltransferase activity of MOF is required forMLL-AF9leukemogenesis, 2017-02-15
Resistance mechanisms to SYK inhibition in acute myeloid leukemia, 2019-11-26
mTOR Complex 1 Plays Critical Roles in Hematopoiesis andPten-Loss-Evoked Leukemogenesis, 2012-09-07
AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias, 2011-09-02
KRasG12D-evoked leukemogenesis does not require ß-catenin, 2013-11-05
Cell of origin determines clinically relevant subtypes ofMLL-rearranged AML, 2012-12-13
Antigen presentation safeguards the integrity of the hematopoietic stem cell pool, 2022-05-05
Pathprinting: An integrative approach to understand the functional basis of disease, 2013-07-26
NUP98-Fusion Proteins Interact With the NSL and MLL1 Complexes To Drive Leukemogenesis, 2016-11-23
Focus on Breast Cancer
Locations
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Affiliated Hospitals
Compare Providers
Providers shown based on Dr. Armstrong's location and specialty. Show more Pediatric Oncologists & Pediatric Hematologists.